How did we come from a great presentation like that to the crappy one for an ipo listtingand i agree whole hartedly get another pr person and keep investors informed
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling